Skip to main content

Wall Street's top pot analyst loves Cronos deal for Altria: 'Unique entry into cannabis'

Wall Street's top marijuana analyst likes Marlboro maker Altria's $1.8 billion investment in Canadian pot company Cronos Group, telling clients the move represents a "unique entry into cannabis."
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.